CHARLOTTESVILLE, VA — July 28, 2004 – Diffusion Pharmaceuticals LLC, a privately held early-stage pharmaceutical company discovering and developing novel small-molecule therapeutics to treat hypoxia (oxygen deprivation at the cellular level), today announced that it has completed a $2.1 million private equity round. These proceeds, along with a $1.2 million grant (N00014-04-C-0146) recently awarded to [...]

CHARLOTTESVILLE, VA — Monday, February 9, 2004 — David G. Kalergis, JD/MBA, CEO of Diffusion Pharmaceuticals LLC, today announced that the company has received a $1.2 million grant (N00014-04-C-0146) from the Office of Naval Research (ONR) to support the transition of its novel small-molecule drug, trans sodium crocetinate (TSC), from animal to human testing. More [...]